Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Impact of minimal residual disease and next generation sequencing discordance in AML following induction with hypomethylating agent + venetoclax.

View Full Paper
Ask AI
Bookmark
Share

Authors

PCPatton CrokerJAJean-Sebastien AnomaJAJonathan Alexánder

Discussion

Loading...

Member takes

Overview

Retrospective analysis shows minimal residual disease and next generation sequencing discordance affects survival in AML, indicating assessment method importance.

Key Points

  • Survival rates differed significantly based on MRD and NGS testing concordance in AML patients after treatment.
  • Median overall survival reached 909 days for MRD(-)/NGS(+) group, contrasting sharply with other classifications.
  • Retrospective study analyzed the impact of MRD testing on patient outcomes after induction with high-intensity therapies.
  • Disparities in MRD and NGS results suggest clearer prognostic criteria are needed for acute myeloid leukemia.

Cite This Study

Croker et al. (2025) studied this question.

synapsesocial.com/papers/69362f444fa91c937236d5c5https://doi.org/10.1182/blood-2025-7047
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A novel multi-target NGS application for molecular monitoring of measurable residual disease in Acute Myeloid Leukemia2025 · 2 citations
  2. 2Prognostic impact of MRD negativity in AML patients treated with venetoclax-based therapy: A systematic review and meta-analysis2025
  3. 3Integration of Next-Generation Sequencing in Measurable Residual Disease Monitoring in Acute Myeloid Leukemia and Myelodysplastic Neoplasm2025 · 5 citations
  4. 4Post-induction minimal residual disease assessment by flow cytometry and molecular biology enables prognostic stratification of patients with NPM1-mutated Acute Myeloid Leukemia: A dataml registry study.2025
  5. 5Comparative evaluation of NGS-based MRD detection in AML using longitudinal matched bone marrow and blood samples2025